PHARMACOLOGIE FONDAMENTALE

Hijona E, Aguirre L, Pérez-Matute P, Villanueva-Millán MJ, Mosqueda-Solis A, Hasnaoui M, Nepveu F, Senard JM, Bujanda L, Aldámiz-Echevarría L, Llarena M, Andrade F, Perio P, Leboulanger F, Hijona L, Arbones-Mainar JM, Portillo MP, Carpéné C. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat : gut microbiota, metabolic, endocrine, and cardiac aspects. J Physiol Biochem. 2016 ;72:567-82.

Galandrin S, Onfroy L, Poirot MC, Sénard JM, Galés C. Delineating biased ligand efficacy at 7TM receptors from an experimental perspective. Int J Biochem Cell Biol. 2016 ;77:251-63.

Galandrin S, Denis C, Boularan C, Marie J, M’Kadmi C, Pilette C, Dubroca C, Nicaise Y, Seguelas MH, N’Guyen D, Banères JL, Pathak A, Sénard JM, Galés C. Cardioprotective Angiotensin-(1-7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor. Hypertension. 2016 ;68:1365-1374.

PHARMACOLOGIE CLINIQUE

Barbagallo G, Sierra-Peña M, Nemmi F, Traon AP, Meissner WG, Rascol O, Péran P. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord.2016 ;31:325-34.

Bonenfant D, Rompré PH, Rei N, Jodoin N, Soland VL, Rey V, Brefel-Courbon C, Ory-Magne F, Rascol O, Blanchet PJ. Characterization of Burning Mouth Syndrome in Patients with Parkinson’s Disease. J Oral Facial Pain Headache. 2016 ;30:318-322.

Bouvenot G, Bounhoure JP, Montastruc JL , Vacheron A. Rapport sur les anticoagulants oraux directs (AOD), (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). Bull. Acad. Natle Méd..2014 ;198:1157-1195.

Breu-Dejean N, Driot D, Dupouy J, Lapeyre-Mestre M, Rostaing L. Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients : 10-Year Results of a Prospective Randomized Study. Exp Clin Transplant. 2016 ;14:38-44.

Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C. Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients : A Randomized Controlled Trial. PLoS One. 2016 ;11:e0162646.

Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O ; NS-Park network. French consensus procedure for assessing cognitive function in Parkinson’s disease. Rev Neurol (Paris). 2016 ;172:696-702.

Dupouy J. Study protocol of the ESUB-MG cluster randomized trial : a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients. Bmc Family Practice. 2016 ;17:24.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P ; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Lancet Neurol. 2016 ;15:154-65.

Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O. Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease : Results of n-of-1 Trials. Front Neurol. 2016 ;7:27.

Giroud JP, Montastruc JL. Séance thématique : La Pharmacoépidémiologie. Bull Acad Natle Med. 2015 ;199:261-62.

Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destée A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A ; French Parkinson’s Disease Genetics Study (PDG). International Parkinson’s Disease Genomics Consortium (IPDGC).. Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet. 2016 Mar 3 ;98:500-13.

Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord. 2016 ;31:1602-1609.

Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG. European MSA Study Group. New insights into orthostatic hypotension in multiple system atrophy : a European multicentre cohort study. J Neurol Neurosurg Psychiatry. 2016 ;87:554-61.

Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Rev Neurother. 2016 ;16:245-58.

Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016 ;30:703-17.

Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, Cuny E, Derost P, Eusebio A, Guehl D, Laurencin C, Mertens P, Ory-Magne F, Raoul S, Regis J, Ulla M, Witjas T, Burbaud P, Rascol O, Damier P. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016 ;86:651-9.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW ; AFU Investigators.. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016 ;31:1489-1496.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson’s Disease-Associated Chronic Pain. J Clin Pharmacol. 2016 ;56:852-61.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O’Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H ; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.. A genome-wide association study in multiple system atrophy. Neurology. 2016 ;87:1591-1598.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson’s Disease. Mov Disord. 2016 ;31:1373-80.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord. 2016 ;31:1049-54.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Alberto C, Konstantinou MP, Martinage C, Casassa E, Tournier E, Bagheri H, Sibaud V, Mourey L, Mazereeuw-Hautier J, Meyer N, Paul C, Bulai Livideanu C. Enzalutamide induced acute generalized exanthematous pustulosis. J Dermatol Case Rep. 2016 ;10 : 35-38.

Audemard-Verger A, Martin Silva N, Verstuyft C, Costedoat-Chalumeau N, Hummel A, Le Guern V, Sacré K, Meyer O, Daugas E, Goujard C, Sultan A, Lobbedez T, Galicier L, Pourrat J, Le Hello C, Godin M, Morello R, Lambert M, Hachulla E, Vanhille P, Queffeulou G, Potier J, Dion JJ, Bataille P, Chauveau D, Moulis G, Farge-Bancel D, Duhaut P, Saint-Marcoux B, Deroux A, Manuzak J, Francès C, Aumaitre O, Bezanahary H, Becquemont L, Bienvenu B. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. PLoS One. 2016 ;11:e0151696.

Authier N, Binder P, Dupouy J, Di Patrizio P, Gentile G, Kahn JP, Lapeyre-Mestre M, Laporte C, Letrilliart L, Maynié C, Micallef J, Mallaret M, Oustric S, Perault-Pochat MC. MG Study Group.. Study protocol of the ESUB-MG cluster randomized trial : a pragmatic trial assessing ESUB-the implementation of urine drug screening in general practice for buprenorphine maintained patients. BMC Fam Pract. 2016 ;17:24..

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : What is the usefulness of the social networks in pharmacovigilance ?. Therapie. 2016 ;71:235-39.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : les réseaux sociaux sont-ils utiles en pharmacovigilance ?. Therapie. 2016 ;71:229-33.

Bagheri H, Laroche ML, Montastruc JL. Les nouveaux défis de la pharmacovigilance. Therapie. 2 016 ;71:119-20.

Bagheri H, Laroche ML, Montastruc JL. Pharmacovigilance : The new challenges. Therapie. 2016 ;71:121-22.

Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, Hillaire-Buys D, Micallef J, Gautier S ; French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors : A Case/Non-Case study in the French Pharmacovigilance Database. Br J Dermatol. 2016 ;175:296-301.

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016 ;11:549-552.

Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016 ;71:223-28.

Bondon-Guitton E, Despas F, Becquemont L. Apport de la Pharmacogénétique à la pharmacovigilance. Therapie. 2016 ;71:217-22.

Bounhoure JP, Bouvenot G, Montastruc JL. Cardiovascular risks and nonsteroidal anti-inflammatory drugs in the elderly recommendations for prescription. Bull. Acad. Natle Méd., 2015 ;199:949-957.

Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people : Literature review and data from the French Database of Pharmacovigilance. Ann Endocrinol (Paris). 2016 ;77:14-21.

Cailhol L, Francois M, Thalamas C, Garrido C, Birmes P, Pourcel L, Lapeyre-Mestre M, Paris J. Is borderline personality disorder only a mental health problem ? Personal Ment Health. 2016 ;10:328-336.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. Atropinic (Anticholinergic) Burden in Parkinson’s Disease. Mov Disord. 2016 ;31:632-6.

Conte C, Rueter M, Laurent G, Bourrel R, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin’s lymphoma : a cohort study of the French national health insurance database. Support Care Cancer. 2016 ;24:4791-9.

Durrieu G, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, Montastruc JL. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre : A Descriptive Study. Drug Saf. 2016 ;39:1189-1195.

Faillie JL, Hillaire-Buys D. Examples of how the pharmaceutical industries distort the evidence of drug safety : the case of pioglitazone and the bladder cancer issue. Pharmacoepidemiol Drug Saf. 2016 ;25:212-4.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. L’apport de la pharmaco-épidémiologie à la pharmacovigilance. Therapie. 2016 ;71:203-09.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016 ;71:211-16.

Giroud JP, Montastruc JL. Les médicaments du rhume à base de vasoconstricteurs doivent être prescrits sur ordonnance. Bull. Acad. Natle Méd..2015 ;199:947-48.

Guinard E, Bulai Livideanu C, Barthelemy H, Viguier M, Reguiai Z, Richard MA, Jullien D, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery MC, Amelot F, Konstantinou MP, Bagheri H, Paul C ; for the French Psoriasis Research Group. Active tuberculosis in psoriasis patients treated with TNF antagonists : a French nationwide retrospective study. JEADV. 2016 ;30:1336-41.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, M Isabel Lucena M, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Yue QY, K E Magnusson P, Wadelius M, for the EuDAC collaborators*. Genetic variants associated with antithyroid drug-induced agranulocytosis : a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016 ;4:507-16.

Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, Bagheri H. Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years. Eur J Clin Pharmacol. 2016 ;72:631-9.

Laconi S, Caihol L, Pourcel L, Thalamas C, Lapeyre-Mestre M, Chabrol H. Personnality disorders sreening with the French version of the Personality diagnostic questionnaire-4+ in a psychiatric population : A preliminary study. Ann Med Psy. 2016 ;174:39-44.

Lamy S, Bettiol C4, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system : an observational cohort study. BMC Health Serv Res. 2016 ;16:336.

Lapeyre-Mestre M. Adverse effects of drugs for respiratory allergy : Is this related to chronic use of anti-H1 drugs ?. Rev. Fran. Allergol.2016 ;56:492-93.

Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F. Mania associated to Ranitidine : a case report and review of literature. Fundam Clin Pharmacol. 2016 ;30:294-6.

Montastruc F, Montastruc G, Montastruc JL, Revet A. Cardiovascular safety of methylphenidate should also be considered in adults !. Bmj. 2016 ;353:i3418.

Montastruc JL, Sommet A, Montastruc F, Moulis G, Bagheri H, Damase-Michel M, Lapeyre-Mestre M. Qu’est-ce que la pharmacoépidémiologie. Pharmacoepidemiology : definition, methods and applications. Bull Acad Natle Med. 2015 ;199:263-73.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance : Risques et effets indésirables de l’automédication. Therapie. 2016 ;71:249-255.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance, risks and adverse effects of self-medication. Therapie. 2016 ;71:257-262.

Montastruc JL, Chebane L, Bagheri H. Comment on : "Drug-Induced Hyperglycaemia and Diabetes". Drug Saf. 2016 ;39:465-66.

Moulis G, Luxembourger C, Tournier E, Pugnet G, Astudillo L, Laurent G, Arlet P, Sailler L, Samson M. Asthenia and chronic joint pain in a 73-year-old woman. Rev Med Interne. 2016 ;37:292-95.

Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, Svenungsson E, Ruggeri M, Mahévas M, Gerfaud-Valentin M, Brainsky A, Michel M, Godeau B, Lapeyre-Mestre M, Sailler L. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies : A systematic review and meta-analysis. Autoimmun Rev. 2016 ;15:203-9.

Moulis G, Germain J, Adoue D, Beyne-Rauzy O, Derumeaux H, Sailler L, Lapeyre-Mestre M. Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. Eur J Intern Med. 2016 ;32:e21-e22.

Olivier-Abbal P. Mesure de l’évitabilité des effets indésirables médicamenteux en France : état des lieux en 2015. Therapie. 2016 ;71:187-194.

Olivier-Abbal P. Measuring the preventability of adverse drug reactions in France : A 2015 overview. Therapie. 2016 ;71:195-202.

Olivier-Abbal P, Gimbert A, Colin AL, Salvo F, Becker M, Marty V, Montastruc JL, Petitpain N. Serious adverse drug events related to non-investigational drugs in academic clinical trials : another source of safety data for risk assessment ? Br J Clin Pharmacol. 2016 ;82:1069-75.

Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fund Clin Pharm. 2016 ;30:616-624.

Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis : Effect of Statin Exposure. A French Population-based Study. J Rheumatol. 2016 ;43:2162-2170.

Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. Drug-drug interactions with imatinib : An observational study. Medicine (Baltimore). 2016 ;95:e5076.

Sahli L, Lapeyre-Mestre M, Derumeaux H, Moulis G. Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. Pharmacoepidemiol Drug Saf. 2016 ;25:785-89.

Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone : a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol. 2016 ;30:162-71.

Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, Bagheri H. Proton pump inhibitors : Real indication or trivialized prescription ?. Therapie. 2016 ;71:589-93.

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib : a case report. J Clin Pharm Ther. 2016 ;41:360-61.

Villars H, Montastruc JL, Despas F. Medication errors and look-alike tablets : the splitting issue. Pharmacoepidemiol Drug Saf. 2016 ;25:1002-3.

MEDECINE ET REPRODUCTION

Beau AB, Montastruc JL, Lacroix I, Montastruc F, Hurault-Delarue C, Damase-Michel C. Atropinic burden of drugs during pregnancy and psychological development of children : a cohort study in the EFEMERIS database. Br J Clin Pharmacol. 2016 ;82:478-486.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women ? Pharmacoepidemiol Drug Saf. 2016 ;25:770-77.

Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssière C, Montastruc JL, Montastruc F, Lacroix I. Psychomotor developmental effects of prenatal exposure to psychotropic drugs : a study in EFEMERIS database. Fund Clin Pharmacol. 2016 ;30:476-482.

Lacroix I, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C. First epidemiological data for venotonics in pregnancy from the EFEMERIS database. Phlebology. 2016 ;31:344-8.

Montastruc F, Salvo F, Arnaud M, Bégaud B, Pariente A. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias : A Disproportionality Analysis Using Data from Vigibase®. Drug Saf. 2016 ;39:689-96.

Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, Lacroix I, Damase-Michel C. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity : a population-based cohort study. Pharmacol Res. 2016 ;113:557-52.

Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A ; EPIGREN study group. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. Transplantation. 2016 ;100:640-7.

ADDICTOVIGILANCE

Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clin Drug Investig. 2016 ;36:735-42.

De Souto Barreto P, Lapeyre-Mestre M, Cestac P, Vellas B, Rolland Y. Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation. Br J Clin Pharmacol. 2016 ;81:759-67.

Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M.  Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie. 2016 ;71:575-78.

Dupouy J, Lapeyre-Mestre M, Oustric S. Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder : a commentary. Pain. 2017 ;158:6-7.

Lapeyre-Mestre M.  A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia. Drugs Aging. 2016 ;33:865-888.

Roussin A, Palmaro A, Lapeyre-Mestre M. Weak Opioid Analgesics Abuse and Addiction : A Comparison of the Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and Tramadol. Neuropathology of Drug Addictions and Substance Misuse. 2016 ;3:375-391.

Spadari M, Batisse A, Guerlais M, Boucher A, Daveluy A, Le Boisselier R, Gibaja V, Eiden C, Lepelley M, Roussin A, Deheul S, Frauger E, Debruyne D. The current aspects of the use of ecstasy/MDMA in France. Therapie. 2016 ;71:553-562.